May 13 (Reuters) - Merck said on Monday it had discontinued the arm of a late-stage study, which tested an experimental antibody-based drug with its blockbuster immunotherapy Keytruda for some patients with the most severe form of skin cancer. (Reporting by Mariam Sunny in Bengaluru; Editing by Tasim Zahid)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
130.7 USD | +0.11% | +4.09% | +19.86% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.86% | 331B | |
+45.82% | 765B | |
-6.16% | 354B | |
+9.32% | 299B | |
+18.91% | 248B | |
-1.55% | 219B | |
+11.29% | 216B | |
+5.90% | 164B | |
-0.73% | 162B | |
+0.18% | 123B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck stops skin cancer combination therapy testing in late-stage study